Indoco Remedies (INDOCO) Share Price Falls 8.60% to Rs 240.65
- September 15, 2026
- Posted by: Harsh Piplani
- Category: News
Indoco Remedies Share Price fell to Rs 240.65 on 15 September 2026, down 8.60% for the day, taking the company’s market capitalisation to Rs 2,430.35 crore. The Small Cap pharmaceutical stock has drawn attention because the decline was sharp, the stock closed near the day’s low, and the available data shows a notable gap between current valuation and underlying profitability metrics.
Today’s move is relevant for anyone tracking Indoco Remedies Share Price Today, Indoco Remedies Stock News and broader Healthcare sector developments. The supplied data confirms the price fall, but it does not establish a company-specific catalyst behind the decline. What it does show is a stock that opened near the previous close, moved briefly higher, and then weakened materially through the session. Investors tracking this Indoco Remedies Share Price Update will also note that the stock still sits above its 50-day and 200-day moving averages, while its P/E ratio remains far above the Pharmaceuticals & Drugs industry median despite weak ROE and modest ROCE. That combination is why the stock is trending in today’s market update on Univest.
Indoco Remedies (INDOCO) Share Price Today: Price Action Analysis
| Metric | Value |
|---|---|
| Current Price | Rs 240.65 |
| Previous Close | Rs 263.3 |
| Today's Move | -Rs 22.65 (-8.6%) |
| Open | Rs 263 |
| High | Rs 265.15 |
| Low | Rs 240.65 |
| Turnover | Rs 0.64 crore |
| Market Capitalisation | Rs 2,430.35 crore |
| Market Cap Category | Small Cap |
Indoco Remedies Share Price Today reflected a distinctly weak trading session, with the stock falling from levels close to the prior close and ending at the session low. The stock opened at Rs 263.00 against a previous close of Rs 263.30, touched an intraday high of Rs 265.15, and then slipped steadily to an intraday low of Rs 240.65, which also matched the current price. That left the stock down Rs 22.65, or 8.60%, on the day.
The intraday range itself is important. A move from Rs 265.15 to Rs 240.65 shows that sellers remained in control after the early high, and the fact that the last quoted price matched the day low suggests the weakness was not fully reversed by the close of the observed window. Turnover stood at Rs 0.64 crore, which confirms active price discovery even in a Small Cap counter with a market capitalisation of Rs 2,430.35 crore. For readers searching Indoco Remedies Share News or Indoco Remedies Stock Falling Today, the clean takeaway is simple: this was a sharp same-day price decline, and the next question is whether the technical and financial backdrop offers support for closer tracking on Univest.
Indoco Remedies (INDOCO) Fundamental Analysis
| Metric | Value |
|---|---|
| Market Capitalisation | Rs 2,430.35 crore |
| P/E Ratio | 431.68x |
| P/B Ratio | 2.43x |
| ROE | -10.13% |
| ROCE | 0.79% |
| EPS | Rs 0.61 |
| Book Value Per Share | Rs 108.15 |
| Dividend Yield | 0.08% |
Indoco Remedies Fundamental Analysis presents a mixed picture. On valuation, the stock trades at a P/E ratio of 431.68 and a P/B ratio of 2.43. On profitability, ROE stands at -10.13% and ROCE at 0.79%, which is a weak combination relative to the valuation multiple. EPS is Rs 0.61, indicating low earnings per share relative to the current stock price, while book value per share is Rs 108.15. At Rs 240.65, the market is assigning a little over two times book value, consistent with the P/B ratio of 2.43.
Dividend yield is 0.08, which signals only a historical payout relative to the current market price. Market capitalisation at Rs 2,430.35 crore places the company in the Small Cap bracket, which is company-size context rather than a quality judgment. The main tension in the numbers is that a very high earnings multiple is being carried alongside negative ROE and only 0.79% ROCE. That does not, by itself, explain today’s decline, but it does explain why Indoco Remedies Stock Analysis is likely to focus heavily on whether valuation and profitability are aligned. For Univest readers following Indoco Remedies Earnings or company financials, that mismatch is the core fundamental issue to monitor.
Sector and Industry Context
| Metric | Value |
|---|---|
| Sector | Healthcare |
| Industry | Pharmaceuticals & Drugs |
| Benchmark Scope | same industry |
| Company P/E Ratio | 431.68x |
| Benchmark Median P/E | 32.72x |
| Benchmark Average P/E | 49.15x |
| Benchmark P/E Range | 3.34x to 693.7x |
| Company P/B Ratio | 2.43x |
| Benchmark Median P/B | 3.05x |
| Benchmark Average P/B | 4.37x |
| Company ROE | -10.13% |
| Benchmark Median ROE | 11.69% |
| Benchmark Average ROE | 10.54% |
| Company ROCE | 0.79% |
| Benchmark Median ROCE | 13.24% |
| Benchmark Average ROCE | 13.09% |
| Company Market Capitalisation | Rs 2,430.35 crore |
| Benchmark Median Market Cap | Rs 704.59 crore |
| Benchmark Average Market Cap | Rs 13,873.11 crore |
Indoco Remedies operates in the Healthcare sector and the Pharmaceuticals & Drugs industry, so the most useful benchmark is the same-industry snapshot rather than the broader market. Across 204 companies in the same industry, the company’s valuation and return ratios look unusual: its P/E of 431.68 is far above the industry median of 32.72 and average of 49.15, though still below the maximum observed 693.70. The industry P/E range runs from 3.34 to 693.70 across 169 companies with available P/E data.
By contrast, Indoco’s P/B of 2.43 is below the industry median of 3.05 and average of 4.37, within a P/B range of -21.33 to 33.78 across 203 companies. Profitability is where the gap is clearer. Company ROE of -10.13% sits below the industry median of 11.69% and average of 10.54, while ROCE of 0.79% is also below the median of 13.24% and average of 13.09 across 203 companies. On size, Indoco Remedies Market Cap of Rs 2,430.35 crore is above the industry median market cap of Rs 704.59 crore but well below the average of Rs 13,873.11 crore, with the industry spanning from Rs 3.80 crore to Rs 4,41,957.50 crore. For anyone tracking Indoco Remedies Share Price Fall, the sector data suggests the stock is being judged against a pharma pack where returns are generally stronger and valuations are usually lower than the company’s current P/E.
Peer Comparison
| Company | Symbol | Market Cap (Cr) | P/E | P/B | ROE (%) | ROCE (%) |
|---|---|---|---|---|---|---|
| Sun Pharmaceutical Industries | SUNPHARMA | 4,41,957.5 | 36.54 | 5.11 | 14.85 | 19.11 |
| Divi's Laboratories | DIVISLAB | 2,47,576 | 84.64 | 14.02 | 16.19 | 21.51 |
| Torrent Pharmaceuticals | TORNTPHARM | 1,89,233.01 | 86.76 | 21.08 | 26.76 | 19.27 |
| Zydus Lifesciences | ZYDUSLIFE | 1,11,670.55 | 24.74 | 4.14 | 19.69 | 21.39 |
| Cipla | CIPLA | 1,10,272.68 | 32.72 | 3.14 | 11.83 | 16 |
Peer comparison sharpens that point. Against major listed Pharmaceuticals & Drugs peers, Indoco’s market capitalisation of Rs 2,430.35 crore is far smaller than Sun Pharmaceutical Industries at Rs 4,41,957.50 crore, Divi’s Laboratories at Rs 2,47,576 crore, Torrent Pharmaceuticals at Rs 1,89,233.01 crore, Zydus Lifesciences at Rs 1,11,670.55 crore and Cipla at Rs 1,10,272.68 crore.
Valuation is even more striking. Indoco’s P/E of 431.68 is above Sun Pharma’s 36.54, Divi’s 84.64, Torrent’s 86.76, Zydus’ 24.74 and Cipla’s 32.72. Its P/B of 2.43 is lower than Sun Pharma’s 5.11, Divi’s 14.02, Torrent’s 21.08, Zydus’ 4.14 and Cipla’s 3.14, but that lower P/B comes alongside weaker profitability. Indoco’s ROE of -10.13% trails Sun Pharma’s 14.85%, Divi’s 16.19%, Torrent’s 26.76%, Zydus’ 19.69% and Cipla’s 11.83%. Its ROCE of 0.79% is also below Sun Pharma’s 19.11%, Divi’s 21.51%, Torrent’s 19.27%, Zydus’ 21.39% and Cipla’s 16.00%. In other words, the peer set shows stronger returns with much lower earnings multiples, which is a key context behind current attention on Indoco Remedies Share Price.
Why Investors Are Watching Indoco Remedies
- The stock declined 8.60% in one session, from a previous close of Rs 263.30 to Rs 240.65.
- It opened at Rs 263.00, touched Rs 265.15, and ended at the day low of Rs 240.65.
- RSI is 59.76, while the stock remains above the 50 DMA of Rs 235.99 and 200 DMA of Rs 221.01.
- P/E at 431.68 is far above the industry median of 32.72 despite ROE of -10.13% and ROCE of 0.79%.
- The company sits in Healthcare and Pharmaceuticals & Drugs, where major peers show stronger return ratios.
About Indoco Remedies
Indoco Remedies is classified within the Healthcare sector and the Pharmaceuticals & Drugs industry. Based on the supplied data, the company is part of a large listed pharma universe where benchmark comparisons span 204 companies. Within that industry context, Indoco is a smaller listed player by market capitalisation than leading peers such as Sun Pharmaceutical Industries, Divi’s Laboratories, Torrent Pharmaceuticals, Zydus Lifesciences and Cipla. For readers following Indoco Remedies Latest News or Indoco Remedies Company News, its current positioning is best understood through pharma-sector valuation, return ratios and market-cap scale rather than broad market narratives.
Track Indoco Remedies Share Price on Univest
UseIndoco Remedies (INDOCO) live share-price page,Univest top decliners screener,Univest market blogsto review live stock data, top decliners and related market analysis.
On Univest, users can track Indoco Remedies Share Price Live with day price action, moving average levels, RSI, valuation ratios, book value, dividend yield, 52-week levels when available, and peer comparisons. Univest also helps investors follow Indoco Remedies Shareholding Pattern when disclosed, sector benchmarks, and ongoing market insights so that today’s move can be placed in a broader stock analysis context.
Disclaimer: Data and figures in this article are sourced from publicly available information. These may or may not be accurate. Please verify all data with the official NSE (nseindia.com) and BSE (bseindia.com) websites before making any investment decision. Investments in securities are subject to market risk. This content is for educational purposes only and is not investment advice by Univest (SEBI RA INH000013776).
Frequently Asked Questions
Why is Indoco Remedies Share Price falling today?
Ans. The supplied data confirms that Indoco Remedies Share Price fell 8.60% to Rs 240.65 from the previous close of Rs 263.30. However, the verified dataset does not identify any company-specific catalyst behind today’s decline.
What is the current Indoco Remedies Share Price Today?
Ans. Indoco Remedies Share Price Today is Rs 240.65. The stock opened at Rs 263.00, touched a high of Rs 265.15, and fell to a low of Rs 240.65, which also matched the current quoted price.
How much did Indoco Remedies stock fall in today’s session?
Ans. The stock declined by Rs 22.65 in today’s session, equal to a fall of 8.60%. It moved from the previous close of Rs 263.30 to Rs 240.65, making it one of the more notable pharma price moves today.
What does today’s price action in Indoco Remedies indicate?
Ans. Today’s price action shows a weak session. The stock opened near the previous close, briefly rose to Rs 265.15, and then slipped to Rs 240.65. Ending at the day low suggests the decline was not meaningfully reversed.
Is Indoco Remedies expensive compared with its industry?
Ans. On P/E, the stock looks expensive versus its industry snapshot. Indoco trades at 431.68 times earnings, compared with the same-industry median of 32.72 and average of 49.15, despite much weaker profitability metrics.
How do Indoco Remedies profitability ratios compare with the industry?
Ans. Indoco Remedies reports ROE of -10.13% and ROCE of 0.79%. Both trail the same-industry median levels of 11.69% ROE and 13.24% ROCE, showing weaker returns than the broader Pharmaceuticals & Drugs benchmark.
What are the key fundamental metrics for Indoco Remedies ?
Ans. Key metrics include market capitalisation of Rs 2,430.35 crore, P/E of 431.68, P/B of 2.43, EPS of Rs 0.61, book value of Rs 108.15, ROE of -10.13%, ROCE of 0.79%, and dividend yield of 0.08.
How does Indoco Remedies compare with major pharma peers?
Ans. Compared with peers such as Sun Pharma, Divi’s, Torrent, Zydus and Cipla, Indoco is much smaller by market cap. Its P/E is higher than all five, while its ROE and ROCE are lower than each of them.
